| InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (NCT04529291) | Fondation Hôpital Saint-Joseph | 2022-04-16 |
| Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf) (NCT05257733) | Centre Hospitalier Universitaire de Nīmes | 2022-03-15 |
| Role of High Frequency Ultrasound in Demyelinating Polyneuropathies (NCT04978623) | Centre Hospitalier Universitaire de Nice | 2022-01-01 |
| Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT04658472) | Bioverativ, a Sanofi company | 2021-04-28 |
| Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing (NCT04356781) | Walton Centre NHS Foundation Trust | 2020-09-28 |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (NCT04561557) | Tongji Hospital | 2020-09-22 |
| Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (NCT03967899) | Fondation Hôpital Saint-Joseph | 2019-07-17 |
| Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial (NCT03584022) | Mayo Clinic | 2018-11-09 |
| Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP (NCT02955355) | Baxalta now part of Shire | 2016-11-14 |
| Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin (NCT02892890) | Assistance Publique Hopitaux De Marseille | 2016-10-19 |
| A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (NCT02549170) | Baxalta now part of Shire | 2015-12-15 |
| Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 (NCT02317562) | Laboratoire français de Fractionnement et de Biotechnologies | 2015-11-01 |
| Efficacy and Safety Study of I10E in Treatment of Patients With CIDP (NCT02293460) | Laboratoire français de Fractionnement et de Biotechnologies | 2015-05-01 |
| Transcriptome Analysis of the Peripheral Blood in CIDP (NCT02404298) | Assistance Publique - Hôpitaux de Paris | 2015-02-01 |
| MRI in Diagnosing and Monitoring CIDP (NCT02017769) | University of Aarhus | 2014-05-01 |
| Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (NCT01625182) | Novartis Pharmaceuticals | 2012-12-22 |
| Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (NCT01225276) | Octapharma | 2011-10-01 |
| Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (NCT00099489) | Biogen | 2004-02-01 |